At present the United States of America is in agreement with Moderna Inc, a drug making company, to acquire 100 million doses of its potential coronavirus vaccine for about the cost of $1.5 billion, the company and White House said within the week.
In recent weeks, the United States has entered into deals to acquire hundreds of millions of doses of potential COVID-19 vaccines from several companies as part of its Operation Warp Speed program, which aims to deliver a vaccine in the country by the end of the year.
The expected Moderna’s price per dose is around $30.50 per person for a two dose regimen.
All the COVID-19 vaccines deals price between $20 to $42 for a two dose course of treatment, with the exception of its deal with AstraZeneca, which offered a lower price per drug in exchange for upfront research and development costs.
As at now, the Moderna’s vaccine candidate, mRNA-1273, is one of the few that have already advanced to the final stage of testing and is on track to be completed in September, the company said this month.
If Moderna’s U.S. deal hits certain unspecific timing benchmarks for vaccine delivery, it will pay out in full.
Already the United States has advanced purchase agreements with Johnson & Johnson, AstraZeneca Plc, Pfizer Inc and BioNTech SE, and Sanofi SA and GlaxoSmithKline Plc for their respective vaccine candidates.
The agreements would lock in more than 500 million doses of COVID-19 vaccine for the U.S., assuming that the companies involved receive regulatory approval. Some deals also give the United States an option to purchase additional doses.
Before now, the U.S. had given Moderna around $1 billion to fund its research efforts, bringing total U.S. funding to around $2.5 billion.
Also some other countries like, Japan, the United Kingdom and Canada, have made similar deals with drugmakers.